Literature DB >> 25705800

The effects of two different doses of hydrocortisone on cognition in patients with secondary adrenal insufficiency--results from a randomized controlled trial.

Jorien Werumeus Buning1, Pauline Brummelman2, Janneke Koerts3, Robin P F Dullaart2, Gerrit van den Berg2, Melanie M van der Klauw2, Oliver Tucha3, Bruce H R Wolffenbuttel2, André P van Beek2.   

Abstract

CONTEXT: A wide variety in hydrocortisone (HC) substitution dose-regimens are considered physiological for patients with secondary adrenal insufficiency (SAI). However, it is likely that cognition is negatively influenced by higher cortisol exposure to the brain.
OBJECTIVE: To examine the effects of a high physiological HC dose in comparison to a low physiological HC dose on cognition. DESIGN AND
SETTING: This study was a randomized double blind cross-over study at the University Medical Center Groningen. This study is registered with ClinicalTrials.gov, number NCT01546922. PATIENTS: Forty-seven patients (29 males, 18 females; mean [SD] age, 51 [14] years, range 19-73) with SAI participated. INTERVENTION(S): Patients randomly received first a low dose of HC (0.2-0.3 mg/kg body weight/day) during 10 weeks followed by a high dose (0.4-0.6 mg/kg body weight/day) for another 10 weeks, or vice versa. HC substitution was given in three divided doses with the highest dose in the morning. MAIN OUTCOME MEASURE(S): Cognitive performance (memory, attention, executive functioning and social cognition) of patients was measured at baseline and after each treatment period using a battery of 12 standardized cognitive tests.
RESULTS: The higher dose of HC resulted in significantly higher systemic cortisol exposure for example measured at 1h after first dose ingestion (mean [SD], low dose: 653 [281] nmol/L; high dose: 930 [148] nmol/L; P<0.001). No differences in cognitive performance were found between the two dose regimens.
CONCLUSIONS: No negative influence on memory, attention, executive functioning and social cognition was observed after 10 weeks of treatment with a higher physiological dose of HC in patients with SAI when compared to a lower dose.
Copyright © 2015 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Cognition; Hydrocortisone; Secondary adrenal insufficiency

Mesh:

Substances:

Year:  2015        PMID: 25705800     DOI: 10.1016/j.psyneuen.2015.02.001

Source DB:  PubMed          Journal:  Psychoneuroendocrinology        ISSN: 0306-4530            Impact factor:   4.905


  5 in total

1.  Pharmacokinetic Modeling of Hydrocortisone by Including Protein Binding to Corticosteroid-Binding Globulin.

Authors:  Eric Rozenveld; Nieko Punt; Martijn van Faassen; André P van Beek; Daan J Touw
Journal:  Pharmaceutics       Date:  2022-05-30       Impact factor: 6.525

2.  Dual-release hydrocortisone and its benefits on cognitive function and quality of sleep.

Authors:  Clarissa Krekeler; Peter Kropp; Antje Katrin Blacha; Amir-Hossein Rahvar; Birgit Harbeck
Journal:  Endocrine       Date:  2021-02-24       Impact factor: 3.633

3.  Somatosensory function in patients with secondary adrenal insufficiency treated with two different doses of hydrocortisone-Results from a randomized controlled trial.

Authors:  Jorien Werumeus Buning; Karl-Heinz Konopka; Pauline Brummelman; Janneke Koerts; Robin P F Dullaart; Gerrit van den Berg; Melanie M van der Klauw; Oliver Tucha; Bruce H R Wolffenbuttel; André P van Beek
Journal:  PLoS One       Date:  2017-07-07       Impact factor: 3.240

4.  Higher hydrocortisone dose increases bilirubin in hypopituitary patients- results from an RCT.

Authors:  Jorien Werumeus Buning; Jenny E Kootstra-Ros; Pauline Brummelman; Gerrit van den Berg; Melanie van der Klauw; Bruce H R Wolffenbuttel; André P van Beek; Robin P F Dullaart
Journal:  Eur J Clin Invest       Date:  2016-04-15       Impact factor: 4.686

5.  Residual endogenous corticosteroid production in patients with adrenal insufficiency.

Authors:  Annet Vulto; Ragnhildur Bergthorsdottir; Martijn van Faassen; Ido P Kema; Gudmundur Johannsson; André P van Beek
Journal:  Clin Endocrinol (Oxf)       Date:  2019-06-20       Impact factor: 3.478

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.